LoadingLoadingCookies show us what works. Privacy
Cookies show us what works. Privacy
LoadingCookies show us what works. Privacy
31 funds hold it · Insiders net selling
Net selling: insiders sold $10.9M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Nov 4, 2026
Financial period
Q3 2026
Earnings per share
$0.74 expected
Revenue
$1.68B expected
Q4 2026 guidance
$1.67B to $1.75B
$1.70B expected+0.6%at the midpoint
Estimates as of Nov 10, 2026
EPS expected
$0.64 to $0.70
Revenue expected
24 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Nov 4, 2026 | $0.80est. $0.74 | +8.62%beat | $1.72Best. $1.68B+2.31% | +10.5%from $1.55B |
| Jun 30, 2026Reported Jul 23, 2026 | $0.78est. $0.74 | +5.25%beat | $1.74BCompany release | +13.6%from $1.53B |
| Mar 31, 2026Reported Apr 23, 2026 | $0.78est. $0.73 | +7.33%beat | $1.65BSEC filing | +16.7%from $1.41B |
| Dec 31, 2025Reported Feb 10, 2026 | $0.58est. $0.62 | -6.27%miss | $1.57BAlpha Vantage | +13.3%from $1.39B |
| Sep 30, 2025Reported Oct 30, 2025 | $0.67est. $0.59 | +13.56%beat | $1.55BSEC filing | +14.7%from $1.35B |
| Jun 30, 2025Reported Jul 24, 2025 | $0.67est. $0.62 | +8.06%beat | $1.53BSEC filing | +11.9%from $1.37B |
| Mar 31, 2025Reported Apr 23, 2025 | Not on file | No estimate | $1.41BSEC filing | +6.2%from $1.33B |
| Dec 31, 2024Reported Feb 11, 2025 | $0.59est. $0.55 | +6.38%beat | $1.39BSEC filing | +9.4%from $1.27B |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $1.57B | $1.65B | $1.74B | $1.72B |
| Cost of what it sold | $340.6M | $359.3M | $390.6M | $369.2M |
| Gross profit | $1.23B | $1.29B | $1.35B | $1.35B |
| What it spent | ||||
| Research and development | $267.7M | $263.3M | $278.9M | $281.4M |
| Sales and admin | $602.9M | $522.2M | $561.2M | $560.9M |
| Other operating costs | -$11.9M | -$10.9M | -$9.2M | — |
| Total operating expenses | $858.7M | $774.6M | $830.9M | $842.3M |
| What was left | ||||
| Operating profit | $370.3M | $514.7M | $519.5M | $299.1M |
| Profit before tax | $90.4M | $459.0M | $519.8M | $363.2M |
| Tax | $26.2M | $78.3M | $278.4M | $61.8M |
| Net profit | $91.2M | $380.7M | $241.9M | $307.5M |
| EBITDA | $133.1M | $499.9M | $562.2M | -$13.3M |
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Anteris Technologies Announces Results for the Third Quarter of 2026
NeutralNov 10Autonomix Medical receives new U.S. patent for catheter sensing technology
Leans bullishNov 10Edwards Lifesciences (NYSE:EW) VP Donald Bobo Jr Sells 48,900 Shares of Stock
Leans bullishNov 9Form 144 Edwards Lifesciences Corp For: 9 November By Investing.com
NeutralNov 9Raised Outlooks and a Cancer Approval Arrive in the Middle of Medicare Open Enrollment
BullishNov 9Edwards Lifesciences stock rating maintained at Buy by TD Cowen
BullishNov 9Edwards Lifesciences CVP Daveen Chopra sells $2.9M in stock
NeutralNov 9Form 4 Edwards Lifesciences Corp: Daveen Chopra (CVP, TMTT, Surgical & IHFM) For: 26 August
NeutralNov 933 macro signals shaping EW right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
